JP2009545595A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009545595A5 JP2009545595A5 JP2009522861A JP2009522861A JP2009545595A5 JP 2009545595 A5 JP2009545595 A5 JP 2009545595A5 JP 2009522861 A JP2009522861 A JP 2009522861A JP 2009522861 A JP2009522861 A JP 2009522861A JP 2009545595 A5 JP2009545595 A5 JP 2009545595A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- poloxamer
- heart failure
- item
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 49
- 229920001983 poloxamer Polymers 0.000 claims description 46
- 229960000502 poloxamer Drugs 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 44
- 206010019280 Heart failures Diseases 0.000 claims description 22
- 239000000565 sealant Substances 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 230000002861 ventricular Effects 0.000 claims description 8
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 230000003205 diastolic effect Effects 0.000 claims description 4
- 230000003834 intracellular effect Effects 0.000 claims description 4
- 210000000170 cell membrane Anatomy 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 229920001993 poloxamer 188 Polymers 0.000 claims description 3
- 229940044519 poloxamer 188 Drugs 0.000 claims description 3
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 2
- 102000004420 Creatine Kinase Human genes 0.000 claims description 2
- 108010042126 Creatine kinase Proteins 0.000 claims description 2
- 101710158332 Diuretic hormone Proteins 0.000 claims description 2
- 101710204261 Diuretic hormone class 2 Proteins 0.000 claims description 2
- 102000001039 Dystrophin Human genes 0.000 claims description 2
- 108010069091 Dystrophin Proteins 0.000 claims description 2
- 102000001708 Protein Isoforms Human genes 0.000 claims description 2
- 108010029485 Protein Isoforms Proteins 0.000 claims description 2
- 102000013394 Troponin I Human genes 0.000 claims description 2
- 108010065729 Troponin I Proteins 0.000 claims description 2
- 102000004987 Troponin T Human genes 0.000 claims description 2
- 108090001108 Troponin T Proteins 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 230000006870 function Effects 0.000 claims description 2
- 230000004217 heart function Effects 0.000 claims description 2
- 230000000302 ischemic effect Effects 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 230000002107 myocardial effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83472806P | 2006-08-01 | 2006-08-01 | |
| US60/834,728 | 2006-08-01 | ||
| PCT/US2007/017182 WO2008016640A2 (en) | 2006-08-01 | 2007-08-01 | Use of poloxamer for the prevention and/or treatment of heart failure |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013189091A Division JP2013253103A (ja) | 2006-08-01 | 2013-09-12 | 慢性進行性心不全のための処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009545595A JP2009545595A (ja) | 2009-12-24 |
| JP2009545595A5 true JP2009545595A5 (https=) | 2011-09-29 |
| JP5537152B2 JP5537152B2 (ja) | 2014-07-02 |
Family
ID=38805633
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009522861A Expired - Fee Related JP5537152B2 (ja) | 2006-08-01 | 2007-08-01 | 慢性進行性心不全のための処置 |
| JP2013189091A Withdrawn JP2013253103A (ja) | 2006-08-01 | 2013-09-12 | 慢性進行性心不全のための処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013189091A Withdrawn JP2013253103A (ja) | 2006-08-01 | 2013-09-12 | 慢性進行性心不全のための処置 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9155758B2 (https=) |
| EP (1) | EP2046348B1 (https=) |
| JP (2) | JP5537152B2 (https=) |
| CN (4) | CN103222984A (https=) |
| AU (1) | AU2007281531B2 (https=) |
| CA (1) | CA2659909A1 (https=) |
| WO (1) | WO2008016640A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2046348B1 (en) | 2006-08-01 | 2015-07-22 | Phrixus Pharmaceuticals, Incorporated | Use of poloxamer for the prevention and/or treatment of heart failure |
| WO2008124088A2 (en) * | 2007-04-05 | 2008-10-16 | Phrixus Pharmaceuticals, Inc. | Compositions and methods for the treatment of heart failure |
| US20130143804A1 (en) * | 2010-06-07 | 2013-06-06 | Trustees Of The University Of Pennsylvania | Islet Amyloid Polypeptide Toxic Oligomer is a Biomarker of Heart or Kidney Failure in Type-2 Diabetes Mellitus |
| EP3057598A1 (en) * | 2013-10-16 | 2016-08-24 | Mast Therapeutics, Inc. | Diuretic induced alterations of plasma volume |
| US9757411B2 (en) | 2014-07-07 | 2017-09-12 | Aires Pharmaceuticals, Inc. | Poloxamer therapy for heart failure |
| JP6747748B2 (ja) | 2014-07-07 | 2020-08-26 | ライフラフト バイオサイエンシーズ，インコーポレイテッド | 長期循環物質のないポロクサマー組成物、その産生方法およびその使用 |
| WO2016007542A1 (en) * | 2014-07-07 | 2016-01-14 | Mast Therapeutics, Inc. | Poloxamer therapy for heart failure |
| US20230190676A1 (en) * | 2020-07-09 | 2023-06-22 | Musc Foundation For Research Development | Methods of protecting cells from insults |
| CN111973623B (zh) * | 2020-08-06 | 2022-04-05 | 温州医科大学 | 心力衰竭靶向治疗的速释制剂 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5198211A (en) | 1986-05-15 | 1993-03-30 | Emory University | Method of treating myocardial damage |
| US5733572A (en) | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
| ES2140408T3 (es) | 1991-03-19 | 2000-03-01 | Cytrx Corp | Copolimeros de polioxipropileno/polioxietileno con actividad biologica mejorada. |
| JPH05178760A (ja) | 1991-06-03 | 1993-07-20 | Alpha Therapeutic Corp | 心筋梗塞治療剤 |
| US5605687A (en) | 1992-05-15 | 1997-02-25 | Arch Development Corporation | Methods and compositions of a polymer (poloxamer) for repair of electrical injury |
| US5994348A (en) | 1995-06-07 | 1999-11-30 | Sanofi | Pharmaceutical compositions containing irbesartan |
| WO2000021543A1 (en) | 1998-10-09 | 2000-04-20 | Cytrx Corporation | Method and composition for treating ischemia and sickle cell anemia |
| US20020013331A1 (en) | 2000-06-26 | 2002-01-31 | Williams Robert O. | Methods and compositions for treating pain of the mucous membrane |
| US6761824B2 (en) | 2000-08-17 | 2004-07-13 | Reeve Lorraine E | Process for the fractionation of polymers |
| WO2002065834A2 (en) | 2000-10-24 | 2002-08-29 | Smithkline Beecham Corporation | Novel formulations of carvedilol |
| WO2003078603A2 (en) | 2002-03-15 | 2003-09-25 | Board Of Regents, The University Of Texas System | Strong gene sets for glioma classification |
| US7550155B2 (en) | 2002-07-29 | 2009-06-23 | Transform Pharmaceuticals Inc. | Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses |
| AU2005289520A1 (en) | 2004-09-27 | 2006-04-06 | Vical Incorporated | Formulations and methods for treatment of inflammatory diseases |
| EP1809272A4 (en) | 2004-10-18 | 2008-01-02 | Maroon Biotech Corp | METHOD AND COMPOSITIONS FOR TREATING DAMAGES THROUGH FREE RADICALS |
| CA2599219C (en) * | 2005-02-25 | 2011-09-20 | The Regents Of The University Of Michigan | Compositions and methods for treating and preventing cardiomyopathy and heart disease |
| DE602006014514D1 (https=) | 2005-03-21 | 2010-07-08 | Santhera Pharmaceuticals Ch | |
| NZ569396A (en) | 2006-02-03 | 2011-06-30 | Nicox Sa | Use of nitrooxyderivative of drug for the treatment of muscular dystrophies |
| EP2046348B1 (en) | 2006-08-01 | 2015-07-22 | Phrixus Pharmaceuticals, Incorporated | Use of poloxamer for the prevention and/or treatment of heart failure |
| WO2008124088A2 (en) | 2007-04-05 | 2008-10-16 | Phrixus Pharmaceuticals, Inc. | Compositions and methods for the treatment of heart failure |
| WO2009078978A2 (en) | 2007-12-14 | 2009-06-25 | Phrixus Pharmaceuticals, Inc. | Compositions containing polyglycidol-based polymers and uses thereof |
| US8852568B2 (en) | 2007-12-17 | 2014-10-07 | The Regents Of The University Of Michigan | Compositions and methods for treating and preventing skeletal muscle deficiencies |
| WO2011066201A2 (en) | 2009-11-25 | 2011-06-03 | The Regents Of The University Of Michigan | Methods and systems for treating and preventing cardiac injury in dystrophic subjects |
-
2007
- 2007-08-01 EP EP07810983.2A patent/EP2046348B1/en not_active Not-in-force
- 2007-08-01 CN CN2013100791323A patent/CN103222984A/zh active Pending
- 2007-08-01 WO PCT/US2007/017182 patent/WO2008016640A2/en not_active Ceased
- 2007-08-01 US US12/309,803 patent/US9155758B2/en not_active Expired - Fee Related
- 2007-08-01 AU AU2007281531A patent/AU2007281531B2/en not_active Ceased
- 2007-08-01 CN CN2011100477182A patent/CN102218077A/zh active Pending
- 2007-08-01 CN CN2013101207279A patent/CN103271935A/zh active Pending
- 2007-08-01 JP JP2009522861A patent/JP5537152B2/ja not_active Expired - Fee Related
- 2007-08-01 CN CNA2007800367818A patent/CN101534843A/zh active Pending
- 2007-08-01 CA CA002659909A patent/CA2659909A1/en not_active Abandoned
-
2013
- 2013-09-12 JP JP2013189091A patent/JP2013253103A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009545595A5 (https=) | ||
| US6894024B2 (en) | Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide | |
| Thompson et al. | Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER | |
| DK2683393T3 (en) | TRIPEPTIME COMPOSITIONS AND THEIR USE IN TREATING DIABETES | |
| CN103179978A (zh) | Ave0010用于制造供治疗2型糖尿病用的药物的用途 | |
| JP2015506942A5 (https=) | ||
| CA2966756A1 (en) | Methods of treating ckd using predictors of fluid retention | |
| US10004754B2 (en) | ANP fragment adjuvant therapy to standard of care (SOC) diuretic treatment | |
| Choi et al. | Effects of angiotensin receptor blocker at discharge in patients with heart failure with reduced ejection fraction: Korean Acute Heart Failure (KorAHF) registry | |
| TW202245792A (zh) | 靜脈注射伊司他星用於治療急性心臟衰竭 | |
| CN103402534B (zh) | 用于治疗充血性心力衰竭的治疗方法 | |
| CN111317811B (zh) | 短胜肽用于治疗或预防高血压及其相关疾病的用途 | |
| EP3072521A1 (en) | Use of recombined ganoderma lucidum immunoregulation protein (rlz-8) in preparing drugs for treating tissue fibrosis | |
| Katz et al. | Sacubitril-Valsartan (LCZ696) in the treatment of systemic hypertension: an updated review of neprilysin inhibition combined with angiotensin II receptor blockade | |
| WO2013102921A2 (en) | Hcg - newer treatment modality for type 2 diabetes mellitus (t2dm) | |
| WO2016133069A1 (ja) | 心不全の予防又は治療のための医薬 | |
| Liakos et al. | Canagliflozin for type 2 diabetes: an up-to-date evidence summary | |
| Erdoğan et al. | Sinus tachycardia related to tacrolimus after kidney transplantation in children and young adults | |
| Doumas et al. | Left Ventricular Structure and Clinical Characteristics of Non-Dilated Cardiomyopathy | |
| Wilding | Results of the LEAD-2 study in relation to NICE and ADA/EASD guidelines for the treatment of type 2 diabetes in the UK | |
| EA047888B1 (ru) | Применение производных пиперидин мочевины в качестве инотропных агентов | |
| Accadia et al. | Apical ballooning-like syndrome: Hypocalcemia? What else! | |
| Abdulla et al. | Cardiac and circulatory problems | |
| Zakir et al. | Hypertension in African Americans with heart failure: progression from hypertrophy to dilatation; perhaps not | |
| Payne et al. | D52 MOLECULAR INSIGHT INTO PULMONARY HYPERTENSION: The Matrikine Acetylated Proline-Glycine-Proline (acpgp) Couples Extracellular Matrix Fragmentation To Pulmonary Microvascular Remodeling And Pulmonary Hypertension |